ADAMTS9 and breast cancer: In BC, ADAMTS9‐AS2 downregulation is linked to miR-130a-5p upregulation and tamoxifen resistance (18), while in ovarian cancer this lncRNA targets the miR-182-5p/FOXF2 signaling axis to control tumor progression (19).